Ginkgo Bioworks Holdings (DNA) Operating Income (2020 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly Operating Income came in at -$71.4 million in Q1 2026, up 11.85% YoY from -$63.8 million in Q1 2025, and down 0.88% on a QoQ basis from -$70.8 million in Q4 2025.
Ginkgo Bioworks Holdings (DNA) Operating Income (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 7 years of Operating Income data on file, last reported at -$71.4 million in Q1 2026.
- Quarterly Operating Income rose 11.85% year-over-year to -$71.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$297.7 million (up 35.67% YoY) and the FY2025 annual result came in at -$315.3 million, up 43.68% from the prior year.
- Operating Income fell to -$71.4 million in Q1 2026, from -$70.8 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$55.2 million in Q3 2024 to a low of -$675.4 million in Q1 2022.
- A 5-year average of -$236.0 million and a median of -$178.1 million in 2023 frame the typical range for Operating Income.
- The widest YoY moves for Operating Income: up 86.3% in 2022, down 2355.53% in 2022.
- Tracing DNA's Operating Income over 5 years: stood at -$230.9 million in 2022, then increased by 22.85% to -$178.1 million in 2023, then soared by 41.83% to -$103.6 million in 2024, then soared by 31.71% to -$70.8 million in 2025, then slipped by 0.88% to -$71.4 million in 2026.
- The last three Operating Income figures came in at -$71.4 million (Q1 2026), -$70.8 million (Q4 2025), and -$90.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Ginkgo Bioworks Holdings | 432.60 Mn | 348.06 Mn | 18.44 Mn | -58.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -58.55 Mn |
| Mar 31, 2026 | -71.37 Mn |
| Dec 31, 2025 | -70.75 Mn |
| Sep 30, 2025 | -90.02 Mn |
| Jun 30, 2025 | -65.54 Mn |
| Mar 31, 2025 | -80.97 Mn |
| Dec 31, 2024 | -103.61 Mn |
| Sep 30, 2024 | -55.20 Mn |
| Jun 30, 2024 | -222.95 Mn |
| Mar 31, 2024 | -178.00 Mn |
| Dec 31, 2023 | -178.12 Mn |
| Sep 30, 2023 | -286.39 Mn |
| Jun 30, 2023 | -184.15 Mn |
| Mar 31, 2023 | -215.75 Mn |
| Dec 31, 2022 | -230.86 Mn |
| Sep 30, 2022 | -654.94 Mn |
| Jun 30, 2022 | -647.78 Mn |
| Mar 31, 2022 | -675.37 Mn |
| Dec 31, 2021 | -1.68 Bn |
| Sep 30, 2021 | -26.67 Mn |